Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
Information source: Alcon Research
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bacterial Conjunctivitis
Intervention: Moxifloxacin eye drops (Drug); Moxifloxicin AF Ophthalmic Solution Vehicle (placebo) (Drug)
Phase: Phase 3
Status: Recruiting
Sponsored by: Alcon Research Overall contact:
Alcon Call Center, Phone: 1-888-451-3937
Summary
The purpose of this study is to evaluate the safety and efficacy of Moxifloxacin AF
Ophthalmic Solution compared to Moxifloxacin AF Vehicle in the treatment of bacterial
conjunctivitis in patients one month of age or older.
Clinical Details
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment
Primary outcome: Resolution of bulbar conjunctival injection and conjunctival discharge/exudate at the Day 4/Exit Visit
Secondary outcome: Eradication of pre-therapy pathogens at the Day 4/Exit Visit
Eligibility
Minimum age: 1 Month.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Signs and symptoms of bacterial conjunctivitis in one or both eyes
Exclusion Criteria:
- Under 1 month in age
Locations and Contacts
Alcon Call Center, Phone: 1-888-451-3937
Contact Alcon Call Center for Study Locations, Fort Worth, Texas 76134, United States; Recruiting
Additional Information
Starting date: October 2008
Ending date: February 2011
Last updated: October 22, 2008
|
